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H. Joachim DeegEnglish is a very versatile language in which new
words are readily created and accepted. For example,
some 50 years ago, the beep-beep-beep of Sputnik I
may have caught the Cold War warriors off guard,
but not the scientists and linguists; in no time it seems,
the satellite was said ‘‘to orbit,’’ that is, to travel around
the ‘‘orb,’’ the globe on which we live. We have not
done as well with our transplantation terminology, de-
spite all of the Latin, Greek, and Anglo-Saxon roots on
which we can draw. Although we talk about ‘‘autolo-
gous transplants,’’ just reflect on this term for a mo-
ment: What are we transplanting? We actually are
giving cells back to the individual from whom they
were taken; if anything, the proper term should be
‘‘autoplantation.’’
The past 10 years have seen remarkable develop-
ments in the field of hematopoietic cell transplanta-
tion, including the approaches used to prepare
patients for transplantation so that donor-derived cells
can establish themselves in the marrow space of the pa-
tient and restore normal hematopoietic and immune
functions. The language used to describe the proce-
dures and the resulting effects has considerable room
for improvement, however.
In the early years of modern hematopoietic cell
transplantation for malignant disorders, the ability to
provide hematopoietic stem cells was used to rescue
marrow function. Patients with acute leukemia, for ex-
ample, could be treated with doses of chemotherapy or
radiation that otherwise would have been fatal due to
treatment-induced marrow failure [1]. However, stud-
ies in rodent models showed that even the highest
doses of chemotherapy or radiotherapy that could be
tolerated (ie, did not result in fatal complications otherred Hutchinson Cancer Research Center and the Univer-
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infection) were not sufficient to eradicate all leukemic
blasts [2-4]. The eventual success of transplantation
generally depended on the immunologic effects of (al-
logeneic) donor cells directed at antigens expressed on
leukemic cells in the recipient, the so-called ‘‘graft-
versus-leukemia’’ (GVL) effect. The power of such
an effect was soon confirmed in clinical studies show-
ing that patients who developed graft-versus-host dis-
ease (GVHD), particularly in its chronic form, were at
lower risk for disease progression or relapse compared
with allogeneic transplant recipients even without
clinical evidence of GVHD [5,6] or recipients of trans-
plants from syngeneic twin donors [7,8]. The high-
dose conditioning regimens used at that time, often in-
volving unfractionated total body irradiation (TBI) at
doses of 800 to 1000 cGy (which, particularly in com-
bination with chemotherapy, were considered ‘‘mye-
loablative’’) did not consistently eradicate the disease.
Whereas further dose escalation (chemotherapy, radi-
ation, or both) reduced the incidence of relapse, the
price of that gain was a substantial increase in
regimen-related mortality [9].
The impetus for the development of different,
hopefully less toxic and more effective strategies
came from several directions:
1. Results in patients who had received transplants
from allogeneic donors but relapsed with their dis-
ease after transplantation showed that the infusion
of additional donor cells (obtained from peripheral
blood) after relapse was able to reinduce (lasting) re-
missions, with the success rate depending primarily
on the patient’s underlying disease [10].
2. Other studies demonstrated that preemptive donor
lymphocyte infusion in patients considered at high
risk for relapse could prevent relapse after trans-
plantation [11].
3. Studies in animal models showed that TBI doses
much lower than those traditionally used for trans-
plantation conditioning provided sufficient immu-
nosuppression in the recipient to allow for
engraftment of cells from a major histocompatibil-
ity complex–matched donor [12].
4. Results from multiple clinical trials indicated that
transplantation of donor cells obtained from pe-
ripheral blood after pretreatment with granulocyte653
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from the marrow (peripheral blood progenitor cells
[PBPCs]) was associated with more rapid engraft-
ment and lower frequency of relapse compared
with cells harvested directly from the marrow.
These mobilized cells contain larger proportions
of T lymphocytes and carry an increased risk of
(chronic) GVHD, but also are associated with an
enhanced GVL effect [13,14]. Thus, a substantial
body of information exists suggesting the possibil-
ity of carrying out successful transplantation using
conditioning regimens of lower intensity and thus
lower toxicity, particularly when PBPCs are the he-
matopoietic stem cell source.
It is not surprising that this goal can be achieved
with more than one conditioning regimen, and by
now a large body of literature supports this concept
[15-20]. The descriptions of the various regimens are
confusing, however; for example, investigators have re-
ported on ‘‘conventional’’ compared with ‘‘mini’’
transplantations, on ‘‘high-intensity’’ versus
‘‘reduced-intensity’’ or ‘‘dose-reduced’’ conditioning
regimens, and on ‘‘myeloablative’’ versus ‘‘nonmyeloa-
blative’’ transplantations, with the recent addition of
a ‘‘submyeloablative’’ regimen [21]. This creativeness
is fascinating and entertaining, but is it useful?
In principle, all transplantations performed in pa-
tients with malignant disorders are intended to be
myeloablative, in the sense that the goal is disease erad-
ication. What differs among the various approaches
may be the strategy used to achieve this goal. If this
(ie, myeloablation) is not what we mean when we say
myeloablative, then we should find a more appropriate
and specific term. It is clear that the lower the intensity
of a conditioning regimen, the more we need to rely on
the immune effects mediated by donor cells; as noted
earlier, the requirement for such an effect was already
apparent in studies reported 3 decades ago [5]. Fur-
thermore, a mini-transplantation is ‘‘mini’’ only in
the sense that the conditioning regimen is of lower in-
tensity than regimens used historically; it is still a full
transplantation, intended to replace the patient’s mar-
row with donor-derived marrow cells, and as such is
accompanied by the risk of GVHD. Admittedly, the
frequency and severity of GVHD may be somewhat
lower than that seen in higher-dose regimens, but
GVHD remains a problem even with low-intensity
conditioning [15,22,23]. Moreover, all efforts in clini-
cal hematopoietic cell transplantation are directed, as
they should be, at improving relapse-free survival in
patients. As a part of these efforts, higher-dose condi-
tioning regimens have been continuously modified
with the aim of reducing transplantation-related toxic-
ity and improving outcome. As a result, a very broad
spectrum of conditioning regimens has emerged, rang-
ing from low-dose TBI or antibody plus chemotherapyto multidrug regimens combined with high-dose TBI.
It follows that it is simply not possible to contrast mye-
loablative with nonmyeloablative conditioning—how
myeloablative or nonmyeloablative is a given regimen?
Our goal is always to eradicate the patient’s disease and
replace the patient’s marrow (and thereby immune
function) with donor-derived cells. Unfortunately,
however, the goal of consistently achieving a state of
mixed chimerism associated with tolerance and disease
eradication has not yet been achieved.
Our responsibility is to provide patients and col-
leagues with clear information on procedures and to
offer the best available therapy, regardless of whether
the term that we use to describe the proposed strategy
was coined by our group or by someone else. I propose
that we avoid vague, confusing, and potentially
misleading terminology. I suggest that regimens be de-
scribed by their composition, for example, a low-dose
TBI (eg, 200 cGy, 2 200 cGy) plus fludarabine (eg, 3
 30 mg/m2, 5  50 mg/m2) regimen, a fludarabine
(eg, 3 30 mg/m2, 5  50 mg/m2) plus melphalan
(eg, 140 mg/m2) regimen, and so on. The physician
reader must know (and the patient is entitled to
know) the composition of each regimen and the possi-
ble side effects, both acute and delayed. Journal editors
should enforce a policy of accurately conveying to the
reader what the report describes.
I would not be surprised if someone were to sug-
gest a nomenclature committee to sort things out
and provide guidance. That would be fine, but proba-
bly would be unnecessary if we could agree to clearly
state what we mean.ACKNOWLEDGMENTS
Financial disclosure: The author has nothing to
disclose.
The author thanks Bonnie Larson and Helen
Crawford for their help with manuscript preparation.REFERENCES
1. Thomas ED, Lochte HL Jr., Lu WC, et al. Intravenous infusion
of bone marrow in patients receiving radiation and chemother-
apy. N Engl J Med. 1957;257:491-496.
2. Burchenal JH, Oettgen HF, Holmberg EAD, et al. Effect of to-
tal body irradiation on the transplantability of mouse leukemias.
Cancer Res. 1960;20:425.
3. Barnes DWH, Corp MJ, Loutit JF, et al. Treatment of murine
leukaemia with x-rays and homologous bone marrow: prelimi-
nary communication. BMJ. 1956;2:626-627.
4. Barnes DWH, Loutit JF. Treatment of murine leukaemia with
x-rays and homologous bone marrow II. Br J Haematol. 1957;
3:241-252.
5. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect
of graft-versus-host disease in human recipients of allogeneic
marrow grafts. N Engl J Med. 1979;300:1068-1073.
Biol Blood Marrow Transplant 15:653-655, 2009 655Transplantation Conditioning Regimens6. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leuke-
mia reactions after bone marrow transplantation. Blood. 1990;75:
555-562.
7. Gale RP, Horowitz MM, Ash RC, et al. Identical twin bone mar-
row transplants for leukemia. Ann Intern Med. 1994;120:
646-652.
8. Fefer A, Cheever MA, Thomas ED, et al. Bone marrow trans-
plantation for refractory acute leukemia in 34 patients with iden-
tical twins. Blood. 1981;57:421-430.
9. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic mar-
row transplantation for myelodysplastic syndrome with ad-
vanced disease morphology: a phase II study of busulfan,
cyclophosphamide, and total-body irradiation and analysis of
prognostic factors. J Clin Oncol. 1996;14:220-226.
10. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-
leukemia effect of donor lymphocyte transfusions in marrow
grafted patients. Chronic Leukemia Working Party of the Euro-
pean Group for Blood and Marrow Transplantation. Blood.
1995;86:2041-2050.
11. Slavin S, Or R, Nagler A, et al. Allogeneic cell therapy (alloCT)
for prevention of relapse in high-risk acute leukemia following
allogeneic bone marrow transplantation: control of GVHD by
graded increments of donor lymphocyte infusion [abstract].
Blood. 1996;88:418a.
12. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic
chimerism in DLA-identical littermate dogs given sublethal
total body irradiation before and pharmacological immunosup-
pression after marrow transplantation. Blood. 1997;89:
3048-3054.
13. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of
bone marrow as compared with peripheral-blood cells from
HLA-identical relatives in patients with hematologic cancers.
N Engl J Med. 2001;344:175-181.
14. Schmitz N, Eapen M, Horowitz MM, et al. Long-term outcome
of patients given transplants of mobilized blood or bone marrow:
a report from the International Bone Marrow Transplant Regis-
try and the European Group for Blood and Marrow Transplan-
tation. Blood. 2006;108:4288-4290.15. Mohty M, Blaise D, Faucher C, et al. Inflammatory cytokines
and acute graft-versus-host disease after reduced-intensity
conditioning allogeneic stem cell transplantation. Blood. 2005;
106:4407-4411.
16. Mohty M, Nagler A, Killmann NM. Reduced-intensity condi-
tioning allogeneic stem cell transplantation: hype, reality or
time for a rethink? Leukemia. 2006;20:1653-1654.
17. Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allo-
geneic stem cell transplantation in relapsed and refractory
Hodgkin’s disease: low transplant-related mortality and impact
of intensity of conditioning regimen. Bone Marrow Transplant.
2005;35:943-951.
18. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative
versus reduced-intensity conditioning regimens in the treatment
of acute myeloid leukemia and high-risk myelodysplastic syn-
drome: dose is relevant for long-term disease control after allo-
geneic hematopoietic stem cell transplantation. Blood. 2004;104:
865-872.
19. Ho AYL, Pagliuca A, Kenyon M, et al. Reduced-intensity
allogeneic hematopoietic stem cell transplantation for myelo-
dysplastic syndrome and acute myeloid leukemia with multiline-
age dysplasia using fludarabine, busulphan and alemtuzumab
(FBC) conditioning. Blood. 2004;104:1616-1623.
20. Deeg HJ, Maris MB, Scott BL, et al. Optimization of allogeneic
transplant conditioning: not the time for dogma. Leukemia.
2006;20:1701-1705.
21. Ahmed N, Leung KS, Rosenblatt H, et al. Successful treatment
of stem cell graft failure in pediatric patients using a submyeloa-
blative regimen of campath-1H and fludarabine. Biol Blood Mar-
row Transplant. 2008;14:1298-1304.
22. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-
host disease after nonmyeloablative versus conventional
hematopoietic stem cell transplantation. Blood. 2003;102:
756-762.
23. Couriel DR, Saliba RM, Giralt S, et al. Acute and chronic graft-
versus-host disease after ablative and nonmyeloablative condi-
tioning for allogeneic hematopoietic transplantation. Biol Blood
Marrow Transplant. 2004;10:178-185.
